Fulcrum Therapeutics

Update in progress

FULC (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing small molecules to aid patients with genetically defined diseases in areas of high unmet medical need in the United States. Its lead candidate, pociredir, is a fetal hemoglobin inducer in Phase 1b for sickle cell disease and beta-thalassemia. It also explores Diamond-Blackfan anemia, Bone Marrow Failure Syndromes, and fibrotic disorders, and has a CAMP4 license covering certain compounds, rights, and know-how. Founded in 2015 and based in Cambridge, MA.

Company score

Sentiment: -0.11; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.03; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.02; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.04; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.01; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.05; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive